Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in prevalence of Critical Limb Ischemia
4.2.2 Improvement in health care infrastructure
4.3 Market Restraints
4.3.1 Drug Failure and Drug Recalls
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Devices
5.1.1.1 Embolic Protection Devices
5.1.1.2 Peripheral Dilatation Systems
5.1.2 Medications
5.1.2.1 Antiplatelet Drugs

5.1.2.2 Antihypertensive Agents
5.1.2.3 Lipid-lowering Agents
5.1.2.4 Others
5.1.3 Surgery
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic plc
6.1.2 LimFlow SA
6.1.3 Micro Medical Solutions
6.1.4 Cardiovascular Systems, Inc.
6.1.5 Eli Lilly and Company
6.1.6 Abbott Laboratories
6.1.7 Rexgenero Ltd.
6.1.8 Cesca Therapeutics, Inc
6.1.9 Teva Pharmaceuticals


7 MARKET OPPORTUNITIES AND FUTURE TRENDS